Yahoo India Web Search

Search results

  1. Treatment of Juvenile Idiopathic Arthritis (JIA) The goals of treatment are to: Control inflammation. Reduce pain and stiffness. Prevent joint and organ damage. Preserve and improve joint function. Promote physical and psychosocial growth and development. Achieve remission (little or no disease activity or symptoms).

  2. Mar 1, 2022 · Objective. To provide updated guidelines for pharmacologic management of juvenile idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint (TMJ) arthritis, and systemic JIA with and without macrophage activation syndrome.

    • 13
    • 74, Issue4
    • 01 March 2022
  3. Mar 30, 2022 · The Arthritis Foundation partnered in 2019 with ACR, an international medical society, to produce two sets of JIA treatment guidelines with input from patients. One focuses on screening, monitoring and treating patients with the eye disease uveitis associated with JIA. The other guideline provides therapeutic approaches for three subsets of JIA ...

  4. Aug 12, 2016 · Juvenile idiopathic arthritis (JIA) is a heterogeneous group of conditions which encompasses all forms of arthritis of unknown etiology lasting for at least 6 weeks and with onset before the age of 16 years [ 1 ]. As a result of the lack of pathognomonic features, the diagnosis of JIA is one of exclusion among all possible causes of chronic ...

    • Gabriella Giancane, Alessandro Consolaro, Alessandro Consolaro, Stefano Lanni, Sergio Davì, Benedett...
    • 10.1007/s40744-016-0040-4
    • 2016
    • Rheumatol Ther. 2016 Dec; 3(2): 187-207.
  5. There is no cure for JIA but remission (little or no disease activity or symptoms) is possible. Early aggressive treatment is key to getting the disease under control as quickly as possible. The goals of JIA treatment are to: Slow down or stop inflammation. Relieve symptoms, control pain and improve quality of life. Prevent joint and organ damage.

  6. ment of JIA with oligoarthritis, TMJ arthritis, and systemic JIA as well as for tapering and discontinuing treatment in subjects with inactive systemic JIA. Other aspects of disease management, including factors that influence treatment choice and medication tapering, are discussed. Evidence for all recommendations was graded as low or very low in

  7. People also ask

  8. May 3, 2019 · May 3, 2019. Based on emerging new evidence and expert and patient consensus, a guideline development team organized by the American College of Rheumatology (ACR) and the Arthritis Foundation (AF) released updated recommendations for the treatment of children and adolescents with juvenile idiopathic arthritis (JIA) manifesting as non-systemic ...